Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/5/2025

Aminoglycoside-Induced Ototoxicity Prevention

Mechanisms and Risk Factors

  • Aminoglycosides accumulate in inner ear cells, causing permanent damage to sensory cells and neurons, with risk factors including advanced age, prolonged therapy, high doses, renal impairment, and genetic predisposition 1, 2

Mitigation Strategies

  • Once-daily aminoglycoside dosing may be less toxic and equally efficacious as multiple daily dosing, according to the European Respiratory Society 1, 2
  • High-peak, low-trough dosing strategies may reduce toxicity while maintaining efficacy, as recommended by the Infectious Diseases Society of America 3
  • Adjusting dosing based on renal function and therapeutic drug monitoring is crucial, as suggested by the British Thoracic Society 4, 5
  • The American Thoracic Society recommends considering streptomycin when vestibular toxicity is a concern, as it has been associated with less hearing loss compared to other aminoglycosides 4

Monitoring Recommendations

  • Baseline audiometric testing is recommended for high-risk patients, particularly those with pre-existing renal impairment or advanced age, as advised by the British Thoracic Society 4, 5
  • Regular monitoring of renal function and serum aminoglycoside concentrations is essential to minimize the risk of ototoxicity, according to the European Respiratory Society 4, 5
  • Patients should be instructed to immediately report symptoms of ototoxicity, such as dizziness, vertigo, tinnitus, or hearing changes, as recommended by the British Thoracic Society 4, 5

Administration Considerations

  • Administering the first dose in a supervised setting with personnel trained in resuscitation is recommended, as suggested by the Infectious Diseases Society of America 6
  • Slow infusion rather than rapid administration can reduce the risk of acute vestibular toxicity, according to the European Respiratory Society 1, 2

Ototoxicity of Tobramycin

Mechanism and Clinical Impact

  • The European Respiratory Society suggests that tobramycin accumulates in inner ear cells, causing permanent damage to sensory hair cells and ganglion cells, leading to high-frequency hearing loss, vestibular toxicity, and tinnitus 7

Route-Specific Considerations

  • The European Respiratory Society recommends that intravenous tobramycin carries the highest ototoxicity risk due to systemic absorption, and typical manifestations include high-tone deafness, hypokalemia, and hypomagnesemia 7
  • The European Respiratory Society states that inhaled/nebulized tobramycin shows no evidence of renal or auditory toxicity when used alone at standard doses, but caution is needed when patients receive IV aminoglycosides in addition to high-dose aerosolized antibiotics 8
  • The European Respiratory Society notes that long-term safety studies with higher doses and sensitive monitoring methods are still required for inhaled/nebulized tobramycin, and serum tobramycin levels may vary considerably after aerosol treatment, so monitoring is recommended for high-dose regimens 9

Risk Mitigation Strategies

  • The American Thoracic Society suggests that once-daily dosing is preferable to three-times-daily dosing for IV tobramycin, as it provides comparable efficacy with potentially lower toxicity, allowing higher peak concentrations and reducing overall drug exposure time 10, 7
  • The European Respiratory Society recommends serum tobramycin concentration monitoring to avoid toxic levels, as part of mandatory monitoring for patients receiving tobramycin 8, 7